The Sting: Scope-changing CDMOs

The company wil acquire a third API manufacturing site in Lecco, Italy as of April this year 

FLAMMA is a CDMO with Headquarters near Milan, Italy. As a fully integrated CDMO, we can leverage our 100% self-owned, self-managed facilities, in Italy and China to deliver a stable, reliable supply chain. We specialize in the cGMP manufacturing of APIs, NCEs, RSMs, &Advanced intermediates (NCEs and generics). We use our expertise in high value chiral materials (specifically amino acid related materials) to provide solutions to customers who not only have need for chiral materials but also clients who have other requirements with a various type of chemistries. In addition, we also manufacture specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries, and others.

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

Learn about Flamma in under 1 minutes by viewing this video.

The CDMO says the suite will help to "bring back manufacturing to the US"

A short article that features Kenneth Drew, VP Flamma USA discussing what makes Flamma different from other CDMOs.

Flamma announced the expansion of its Continuous Flow capabilities with the investment of ~$2M

FLAMMA announced the another addition to its Continuous Flow capabilities with the addition of a Corning G4 Microreactor.

FLAMMA announced the commitment to invest $200M over the next three years. This significant investment will propel Flamma forward.